The Experts below are selected from a list of 42798 Experts worldwide ranked by ideXlab platform

William R Hiatt - One of the best experts on this subject based on the ideXlab platform.

  • association of health status scores with cardiovascular and limb outcomes in patients with symptomatic Peripheral Artery disease insights from the euclid examining use of ticagrelor in symptomatic Peripheral Artery disease trial
    Journal of the American Heart Association, 2020
    Co-Authors: William R Hiatt, Lars Norgren, Jeffrey S Berger, Kenneth W Mahaffey, Michael S Conte, Jennifer A Rymer, Hillary Mulder, Kim G Smolderen, Iris Baumgartner
    Abstract:

    Background There are limited data on health status instruments in patients with Peripheral Artery disease and cardiovascular and limb events. We evaluated the relationship between health status cha...

  • major adverse limb events and 1 year outcomes after Peripheral Artery revascularization
    Journal of the American College of Cardiology, 2018
    Co-Authors: Connie N Hess, Kevin R Rogers, Tracy Y Wang, Jacob Gundrum, Nancy Allen M Lapointe, William R Hiatt
    Abstract:

    Abstract Background Revascularization is important for symptom treatment and limb salvage in Peripheral Artery disease, yet little data exist on the incidence of post-procedure major adverse limb events (MALE) and longer-term outcomes. Objectives This study sought to characterize hospitalizations and outpatient endovascular revascularizations after Peripheral Artery revascularization, assess temporal trends for outcomes, and identify factors associated with subsequent MALE hospitalization. Methods Patients undergoing Peripheral Artery revascularization between January 1, 2009, and September 30, 2014, in the Premier Healthcare Database were examined for the primary outcome of 1-year MALE hospitalization. Secondary outcomes included 1-year outpatient endovascular revascularization and limb-related, cardiovascular, and all-cause inpatient hospitalizations. Multivariable logistic regression was used to identify factors associated with 1-year MALE hospitalization. Results Among 381,415 revascularized patients, within 1 year post-index revascularization, 10.3% (n = 10,182) had a hospitalization for MALE, 11.0% (n = 42,056) had an outpatient endovascular revascularization, 18.8% (n = 71,663) had a limb-related hospitalization, 12.8% (n = 48,875) had a cardiovascular hospitalization, and 38.9% (n = 148,457) had any inpatient hospitalization. Over the study period, limb-related, cardiovascular, and all-cause hospitalizations decreased, whereas rates of outpatient endovascular revascularizations increased. Male sex, black race, Medicare and Medicaid insurance, diabetes, renal insufficiency, heart failure, smoking, baseline critical or acute limb ischemia, surgical revascularization, and noncardiology operator specialty were significantly associated with increased risk of MALE hospitalization. Conclusions In contemporary practice, hospitalization for MALE occurs in 1 in 10 patients within 1 year after Peripheral revascularization and is associated with patient and procedural factors. These data may inform efforts to improve post-procedure outcomes and limb-related clinical trial design.

  • tct 339 types of myocardial infarction in patients with Peripheral Artery disease insights from euclid
    Journal of the American College of Cardiology, 2017
    Co-Authors: Christoph B Olivier, William R Hiatt, Lars Norgren, Jeffrey S Berger, Brian G Katona, Frank W Rockhold, Juuso I Blomster, Schuyler Jones, Daniel Wojdyla, Manesh R Patel
    Abstract:

    Patients with Peripheral Artery disease (PAD) are at high risk for myocardial infarction (MI). The characterization of types of MI has not been reported. This analysis aims to characterize types of MI in patients with PAD and the clinical and demographic features of patients with and without MI.

  • ticagrelor compared with clopidogrel in patients with prior lower extremity revascularization for Peripheral Artery disease
    Circulation, 2017
    Co-Authors: Schuyler W Jones, Iris Baumgartner, William R Hiatt, Gretchen Heizer, Jeffrey S Berger, Peter Held, Brian G Katona, Michael S Conte, Christopher J White, Kenneth W Mahaffey
    Abstract:

    Background:In patients with symptomatic Peripheral Artery disease with a history of limb revascularization, the optimal antithrombotic regimen for long-term management is unknown. Methods:The EUCLI...

  • ticagrelor versus clopidogrel in symptomatic Peripheral Artery disease
    The New England Journal of Medicine, 2017
    Co-Authors: William R Hiatt, Iris Baumgartner, Gerry F R Fowkes, Gretchen Heizer, Jeffrey S Berger, Peter Held, Brian G Katona, Kenneth W Mahaffey, L Norgren, Schuyler W Jones
    Abstract:

    BackgroundPeripheral Artery disease is considered to be a manifestation of systemic atherosclerosis with associated adverse cardiovascular and limb events. Data from previous trials have suggested that patients receiving clopidogrel monotherapy had a lower risk of cardiovascular events than those receiving aspirin. We wanted to compare clopidogrel with ticagrelor, a potent antiplatelet agent, in patients with Peripheral Artery disease. MethodsIn this double-blind, event-driven trial, we randomly assigned 13,885 patients with symptomatic Peripheral Artery disease to receive monotherapy with ticagrelor (90 mg twice daily) or clopidogrel (75 mg once daily). Patients were eligible if they had an ankle–brachial index (ABI) of 0.80 or less or had undergone previous revascularization of the lower limbs. The primary efficacy end point was a composite of adjudicated cardiovascular death, myocardial infarction, or ischemic stroke. The primary safety end point was major bleeding. The median follow-up was 30 months. ...

Jeffrey S Berger - One of the best experts on this subject based on the ideXlab platform.

Kunihiro Matsushita - One of the best experts on this subject based on the ideXlab platform.

Emile R Mohler - One of the best experts on this subject based on the ideXlab platform.

  • effects of exercise training on calf muscle oxygen extraction and blood flow in patients with Peripheral Artery disease
    Journal of Applied Physiology, 2017
    Co-Authors: Wesley B Baker, Steven S Schenkel, Malavika Chandra, David R Busch, Erin K Englund, Kathryn H Schmitz, Arjun G Yodh, Thomas F Floyd, Emile R Mohler
    Abstract:

    We report on noninvasive optical measurements of skeletal muscle blood flow and oxygen extraction dynamics before/during/after treadmill exercise in Peripheral Artery disease patients who experienc...

  • multiparametric assessment of vascular function in Peripheral Artery disease dynamic measurement of skeletal muscle perfusion blood oxygen level dependent signal and venous oxygen saturation
    Circulation-cardiovascular Imaging, 2015
    Co-Authors: Erin K Englund, Emile R Mohler, Michael C Langham, Sarah J Ratcliffe, Molly Fanning, Felix W Wehrli, Thomas F Floyd
    Abstract:

    Background— Endothelial dysfunction present in patients with Peripheral Artery disease may be better understood by measuring the temporal dynamics of blood flow and oxygen saturation during reactive hyperemia than by conventional static measurements. Methods and Results— Perfusion, Intravascular Venous Oxygen saturation, and T2* (PIVOT), a recently developed MRI technique, was used to measure the response to an ischemia–reperfusion paradigm in 96 patients with Peripheral Artery disease of varying severity and 10 healthy controls. Perfusion, venous oxygen saturation SvO2, and T2* were each quantified in the calf at 2-s temporal resolution, yielding a dynamic time course for each variable. Compared with healthy controls, patients had a blunted and delayed hyperemic response. Moreover, patients with lower ankle-brachial index had (1) a more delayed reactive hyperemia response time, manifesting as an increase in time to peak perfusion in the gastrocnemius, soleus, and peroneus muscles, and in the anterior compartment, (2) an increase in the time to peak T2* measured in the soleus muscle, and (3) a prolongation of the posterior tibial vein SvO2 washout time. Intrasession and intersession repeatability were also assessed. Results indicated that time to peak perfusion and time to peak T2* were the most reliable extracted time course metrics. Conclusions— Perfusion, dynamic SvO2, and T2* response times after induced ischemia are highly correlated with Peripheral Artery disease severity. Combined imaging of Peripheral microvascular blood flow and dynamics of oxygen saturation with Perfusion, intravascular SvO2, and T2* may be a useful tool to investigate the pathophysiology of Peripheral Artery disease.

  • supervised exercise versus primary stenting for claudication resulting from aortoiliac Peripheral Artery disease six month outcomes from the claudication exercise versus endoluminal revascularization clever study
    Circulation, 2012
    Co-Authors: Timothy P Murphy, Judith G Regensteiner, Donald E Cutlip, Emile R Mohler, David J Cohen, Matthew R Reynolds, Joseph M Massaro, Beth A Lewis, Joselyn Cerezo, Niki C Oldenburg
    Abstract:

    Background— Claudication is a common and disabling symptom of Peripheral Artery disease that can be treated with medication, supervised exercise (SE), or stent revascularization (ST). Methods and Results— We randomly assigned 111 patients with aortoiliac Peripheral Artery disease to receive 1 of 3 treatments: optimal medical care (OMC), OMC plus SE, or OMC plus ST. The primary end point was the change in peak walking time on a graded treadmill test at 6 months compared with baseline. Secondary end points included free-living step activity, quality of life with the Walking Impairment Questionnaire, Peripheral Artery Questionnaire, Medical Outcomes Study 12-Item Short Form, and cardiovascular risk factors. At the 6-month follow-up, change in peak walking time (the primary end point) was greatest for SE, intermediate for ST, and least with OMC (mean change versus baseline, 5.8±4.6, 3.7±4.9, and 1.2±2.6 minutes, respectively; P P =0.02 for ST versus OMC, and P =0.04 for SE versus ST). Although disease-specific quality of life as assessed by the Walking Impairment Questionnaire and Peripheral Artery Questionnaire also improved with both SE and ST compared with OMC, for most scales, the extent of improvement was greater with ST than SE. Free-living step activity increased more with ST than with either SE or OMC alone (114±274 versus 73±139 versus −6±109 steps per hour), but these differences were not statistically significant. Conclusions— SE results in superior treadmill walking performance than ST, even for those with aortoiliac Peripheral Artery disease. The contrast between better walking performance for SE and better patient-reported quality of life for ST warrants further study. Clinical Trial Registration— URL: http://clinicaltrials.gov/ct/show/NCT00132743?order=1. Unique identifier: NCT00132743.

  • supervised exercise versus primary stenting for claudication resulting from aortoiliac Peripheral Artery disease six month outcomes from the claudication exercise versus endoluminal revascularization clever study
    Circulation, 2012
    Co-Authors: Timothy P Murphy, Judith G Regensteiner, Donald E Cutlip, Emile R Mohler, David J Cohen, Matthew R Reynolds, Joseph M Massaro, Beth A Lewis, Joselyn Cerezo, Niki C Oldenburg
    Abstract:

    Background—Claudication is a common and disabling symptom of Peripheral Artery disease that can be treated with medication, supervised exercise (SE), or stent revascularization (ST). Methods and Results—We randomly assigned 111 patients with aortoiliac Peripheral Artery disease to receive 1 of 3 treatments: optimal medical care (OMC), OMC plus SE, or OMC plus ST. The primary end point was the change in peak walking time on a graded treadmill test at 6 months compared with baseline. Secondary end points included free-living step activity, quality of life with the Walking Impairment Questionnaire, Peripheral Artery Questionnaire, Medical Outcomes Study 12-Item Short Form, and cardiovascular risk factors. At the 6-month follow-up, change in peak walking time (the primary end point) was greatest for SE, intermediate for ST, and least with OMC (mean change versus baseline, 5.8±4.6, 3.7±4.9, and 1.2±2.6 minutes, respectively; P<0.001 for the comparison of SE versus OMC, P=0.02 for ST versus OMC, and P=0.04 for ...

  • mean platelet volume and prevalence of Peripheral Artery disease the national health and nutrition examination survey 1999 2004
    Atherosclerosis, 2010
    Co-Authors: Jeffrey S Berger, Luis H Eraso, Emile R Mohler
    Abstract:

    Objectives We sought to determine whether mean platelet volume (MPV) is associated with the prevalence of Peripheral Artery disease (PAD).

Niki C Oldenburg - One of the best experts on this subject based on the ideXlab platform.

  • supervised exercise versus primary stenting for claudication resulting from aortoiliac Peripheral Artery disease six month outcomes from the claudication exercise versus endoluminal revascularization clever study
    Circulation, 2012
    Co-Authors: Timothy P Murphy, Judith G Regensteiner, Donald E Cutlip, Emile R Mohler, David J Cohen, Matthew R Reynolds, Joseph M Massaro, Beth A Lewis, Joselyn Cerezo, Niki C Oldenburg
    Abstract:

    Background— Claudication is a common and disabling symptom of Peripheral Artery disease that can be treated with medication, supervised exercise (SE), or stent revascularization (ST). Methods and Results— We randomly assigned 111 patients with aortoiliac Peripheral Artery disease to receive 1 of 3 treatments: optimal medical care (OMC), OMC plus SE, or OMC plus ST. The primary end point was the change in peak walking time on a graded treadmill test at 6 months compared with baseline. Secondary end points included free-living step activity, quality of life with the Walking Impairment Questionnaire, Peripheral Artery Questionnaire, Medical Outcomes Study 12-Item Short Form, and cardiovascular risk factors. At the 6-month follow-up, change in peak walking time (the primary end point) was greatest for SE, intermediate for ST, and least with OMC (mean change versus baseline, 5.8±4.6, 3.7±4.9, and 1.2±2.6 minutes, respectively; P P =0.02 for ST versus OMC, and P =0.04 for SE versus ST). Although disease-specific quality of life as assessed by the Walking Impairment Questionnaire and Peripheral Artery Questionnaire also improved with both SE and ST compared with OMC, for most scales, the extent of improvement was greater with ST than SE. Free-living step activity increased more with ST than with either SE or OMC alone (114±274 versus 73±139 versus −6±109 steps per hour), but these differences were not statistically significant. Conclusions— SE results in superior treadmill walking performance than ST, even for those with aortoiliac Peripheral Artery disease. The contrast between better walking performance for SE and better patient-reported quality of life for ST warrants further study. Clinical Trial Registration— URL: http://clinicaltrials.gov/ct/show/NCT00132743?order=1. Unique identifier: NCT00132743.

  • supervised exercise versus primary stenting for claudication resulting from aortoiliac Peripheral Artery disease six month outcomes from the claudication exercise versus endoluminal revascularization clever study
    Circulation, 2012
    Co-Authors: Timothy P Murphy, Judith G Regensteiner, Donald E Cutlip, Emile R Mohler, David J Cohen, Matthew R Reynolds, Joseph M Massaro, Beth A Lewis, Joselyn Cerezo, Niki C Oldenburg
    Abstract:

    Background—Claudication is a common and disabling symptom of Peripheral Artery disease that can be treated with medication, supervised exercise (SE), or stent revascularization (ST). Methods and Results—We randomly assigned 111 patients with aortoiliac Peripheral Artery disease to receive 1 of 3 treatments: optimal medical care (OMC), OMC plus SE, or OMC plus ST. The primary end point was the change in peak walking time on a graded treadmill test at 6 months compared with baseline. Secondary end points included free-living step activity, quality of life with the Walking Impairment Questionnaire, Peripheral Artery Questionnaire, Medical Outcomes Study 12-Item Short Form, and cardiovascular risk factors. At the 6-month follow-up, change in peak walking time (the primary end point) was greatest for SE, intermediate for ST, and least with OMC (mean change versus baseline, 5.8±4.6, 3.7±4.9, and 1.2±2.6 minutes, respectively; P<0.001 for the comparison of SE versus OMC, P=0.02 for ST versus OMC, and P=0.04 for ...